• 1
    Joint United Nations Programme on HIV/AIDS and World Health Organization (WHO). AIDS epidemic update. Published December 2007. Accessed December 14, 2007.
  • 2
    National Institute of Allergy and Infectious Diseases. HIV infection in adolescents and young adults in the US. Accessed August 13, 2007.
  • 3
    Prendergast A, Tudor-Williams G, Prakash J, et al. International perspectives, progress and future challenges of paediatric HIV infection. Lancet. 2007;370:6880.
  • 4
    Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study. Pediatrics. 1994;94(6, pt 1):815819.
  • 5
    Chandra RK, Kumari S. Nutrition and immunity: an overview. J Nutr. 1994;124(suppl 8):1433S1435S.
  • 6
    Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS. 2003;17(suppl 1):S130S140.
  • 7
    Miller TL, Orav EJ, Martin SR, et al. Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus 1 infection. Gastroenterology. 1991;100(5, pt 1):12961302.
  • 8
    Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet. 1999;353:20932099.
  • 9
    Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services in collaboration with Centers for Disease Control and Prevention; 2006.
  • 10
    Leonard E, McComsey GA. Metabolic complications of HIV therapy in children. AIDS. 2004;18:17531768.
  • 11
    Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107:E77.
  • 12
    Arpadi SM, Cuff PA, Horlick M, et al. Lipodystrophy in HIV-infected children is associated with high viral load and low CD-4 lymphocyte percentage at baseline and use of protease inhibitor and stavudine. J Acquir Immune Defic Syndr. 2001;27:3034.
  • 13
    Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics. 2004;114:e235e242.
  • 14
    Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr.. 2003;32:482489.
  • 15
    Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr. 2007;166:1321.
  • 16
    Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405410.
  • 17
    Mueller BU, Nelson RP Jr, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics. 1998;101(3, pt 1):335343.
  • 18
    Nadal D, Steiner F, Cheseaux J, et al. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. Infection. 2000;28:287296.
  • 19
    Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr. 2002;30:288293.
  • 20
    Carter RJ, Wiener J, Abrams EJ, et al; on behalf of Perinatal AIDS Collaborative Transmission Study-HIV Follow-Up After Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J Acquir Immune Defic Syndr. 2006;41:453460.
  • 21
    Sharma T, Orav E, Weinberg G, et al. Visceral adiposity and cardiac risk profiles in human immunodeficiency virus-1 infected children. EPAS. 2006;59:5523.132.
  • 22
    Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641649.
  • 23
    Schmitz M, Michl G, Walli R, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;26:225235.
  • 24
    Lewis W. Atherosclerosis in AIDS: potential pathogenic roles of antiretroviral therapy and HIV. J Mol Cell Cardiol. 2000;32:21152129.
  • 25
    Bonnet E, Ruidavets J, Tuech J, et al. Apoprotein c-III and E-containing lipoarticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab. 2001;86:296302.
  • 26
    Lainka E. Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110(5):e56.
  • 27
    Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS. 2003;17:13191327.
  • 28
    Verkauskiene R, Dollfus C, Levine M, et al. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution. Pediatr Res. 2006;60:225230.
  • 29
    Beregszàszi M, Jaquet D, Lévine M, et al. Severe insulin resistance contrasting with mild anthropometric changes in the adipose tissue of HIV-infected children with lipohypertrophy. Int J Obes Relat Metab Disord. 2003;27:2530.
  • 30
    Murata H, Hruz P, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:2025120254.
  • 31
    Grinspoon S. Physiologic effects of GHRH in patients with HIV lipodystrophy: a model of acquired visceral adiposity. Nat Clin Pract Endocrinol Metab. 2006;2:355.
  • 32
    Brinkman K, Smeitinik JA, Romjin JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipogenesis. Lancet. 1999;354:11121115.
  • 33
    Kim RJ, Wilson CG, Wabitsch M, et al. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring). 2006;14:9941002.
  • 34
    Bitnun A, Sochett E, Dick P, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2005;90:168174.
  • 35
    Lipshultz SE, Chanock S, Sanders SP, et al. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol. 1989;63:14891497.
  • 36
    Luginbuhl LM, Orav EJ, McIntosh K, et al. Cardiac morbidity and related mortality in children with HIV infection. JAMA. 1993;269:28692875.
  • 37
    Shearer WT, Lipshultz SE, Easley KA, et al. Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1-disease progressors. Pediatrics. 2000;105(1):e9.
  • 38
    Hornberger LK, Lipshultz SE, Easley KA, et al. Cardiac structure and function in fetuses of mothers infected with HIV: the prospective P2C2 HIV multi-center study. Am Heart J. 2000;140:575584.
  • 39
    Lai WW, Lipshultz SE, Easley KA. Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus infected women. J Am Coll Cardiol. 1998;32:17491755.
  • 40
    Fisher SD, Bowles NE, Towbin JA, et al. Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS. 2003;17(suppl 1):S29S35.
  • 41
    Hurwitz BE, Klimas NG, Llabre MM, et al. HIV, metabolic syndrome X, inflammation, oxidative stress, coronary heart disease risk: role of protease inhibitor exposure. Cardiovasc Toxicol. 2004;4:303316.
  • 42
    Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E261E271.
  • 43
    De Larrañaga GF, Petroni A, Deluchi G, et al. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis. 2003;14:1518.
  • 44
    Wolf K, Tsakiris D, Weber R, et al, for the Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185:456462.
  • 45
    Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation. 2005;112:103199.
  • 46
    National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89(3, pt 2):525584.
  • 47
    Dietary Reference Intake for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride; Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. Washington, DC: Institute of Medicine, Food and Nutrition Board; 19972002.
  • 48
    Sharma T, Kinnamon D, Duggan C, et al. Dietary changes from the pre- to post-HAART eras in HIV-infected children. EPAS. 2007;61:6294.16.
  • 49
    Robinson FP, Quinn LT, Rimmer JH. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. Biol Res Nurs. 2007;8:177185.
  • 50
    Miller TL. A hospital-based exercise program to improve body composition, strength, and abdominal adiposity in 2 HIV-infected children. AIDS Read. 2007;17:450452, 455, 458.
  • 51
    American Heart Association. Exercise (physical activity) and children. Accessed September 6, 2007.
  • 52
    McComsey G, Bhumbra N, Ma JF, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275e281.
  • 53
    Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189e214.
  • 54
    Hayman LL, Meininger JC, Daniels SR, et al. Primary prevention of cardiovascular disease in nursing practice: focus on children and youth. A Scientific Statement From the American Heart Association Committee on Atherosclerosis, Hypertension, and Obesity in Youth of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2007;116:344357.
  • 55
    MedlinePlus. High blood pressure. Accessed September 7, 2007.